Recurrent Vulvovaginal Candidiasis Causes and Risk Factors
Definition and Prevalence
- Recurrent vulvovaginal candidiasis (RVVC) is defined as three or more symptomatic episodes of vulvovaginal candidiasis (VVC) within a 12-month period, according to the Clinical Infectious Diseases guidelines 1
- Approximately 75% of women will experience at least one episode of VVC in their lifetime, with 40-45% experiencing two or more episodes, as reported by the American Academy of Family Physicians 2, 3
- RVVC may affect up to 9% of women, with the highest prevalence (12%) in women aged 25-34 years, according to the Clinical Infectious Diseases guidelines 1
Major Risk Factors for Recurrent Infections
Medical Conditions
- Uncontrolled diabetes mellitus increases susceptibility to fungal infections, including Candida species, as stated by the American Academy of Family Physicians 3
- Immunosuppression from medications or underlying diseases is a risk factor for RVVC, according to the American Academy of Family Physicians and the Centers for Disease Control and Prevention 3, 4
- HIV infection is a risk factor for RVVC, although treatment should not differ from non-HIV infected women, as reported by the American Academy of Family Physicians 2, 3
Medication-Related Factors
- Corticosteroid use is a risk factor for RVVC, as stated by the Centers for Disease Control and Prevention 5
Microbiological Factors
- Non-albicans Candida species are found in 10-20% of RVVC cases and often show reduced susceptibility to standard azole treatments, according to the Centers for Disease Control and Prevention 4
- Development of azole-resistant strains, particularly with prolonged azole exposure, is a concern in RVVC treatment, as reported by the Clinical Infectious Diseases guidelines 6
- pH-dependent drug resistance is a factor in RVVC treatment, as antifungal medications may have higher minimum inhibitory concentrations at vaginal pH (4) compared to laboratory testing pH (7), according to the Clinical Infectious Diseases guidelines 1
Other Contributing Factors
- Genetic predisposition is a possible factor in idiopathic RVVC cases, as stated by the Clinical Infectious Diseases guidelines 1
- Possible underdosing of antifungal medications is a concern in RVVC treatment, according to the Clinical Infectious Diseases guidelines 1
- Pregnancy is a risk factor for RVVC, as reported by the American Academy of Family Physicians 3, 7
Diagnostic Considerations for Recurrent Cases
- Vaginal cultures should be obtained from patients with RVVC to confirm the clinical diagnosis and identify unusual or non-albicans species, particularly C. glabrata, as recommended by the Centers for Disease Control and Prevention 4
Treatment Challenges in Recurrent Cases
- Maintenance therapy is required for long-term control of RVVC, as stated by the Centers for Disease Control and Prevention 4
- Even with maintenance fluconazole for 6 months, recurrence occurs in up to 50% of women after treatment cessation, according to the Clinical Infectious Diseases guidelines 1
Impact on Quality of Life
- RVVC affects approximately 6 million women in the United States and causes an estimated $4.7 billion in lost productivity annually, as reported by the Clinical Infectious Diseases guidelines 1, 8
Common Pitfalls and Caveats
- VVC is not typically acquired through sexual intercourse, but treatment of sex partners may be considered in women with recurrent infection, as stated by the American Academy of Family Physicians 2, 3
- Unnecessary or inappropriate use of over-the-counter preparations can lead to delayed treatment of other causes of vulvovaginitis, as reported by the Centers for Disease Control and Prevention 4
Treatment of Recurrent Vulvovaginal Candidiasis
Initial Treatment and Maintenance
- The Centers for Disease Control and Prevention recommends fluconazole 100 mg daily for up to 6 months as an alternative maintenance regimen 9
- The Centers for Disease Control and Prevention suggests scheduling regular follow-up visits at 3, 6, 9, and 12 months to monitor effectiveness and side effects 9
Special Considerations
- The Centers for Disease Control and Prevention recommends using only topical azole therapy for 7 days in pregnant women 9
- The Centers for Disease Control and Prevention advises against using oral fluconazole during pregnancy 9
- The Centers for Disease Control and Prevention states that partner treatment is not routinely recommended and does not prevent recurrences 9
- The Centers for Disease Control and Prevention recommends treating male partners only if they have symptomatic balanitis with topical antifungal cream 9
Safety Monitoring
- The Centers for Disease Control and Prevention reports that hepatotoxicity with ketoconazole occurs in 1:10,000 to 1:15,000 exposed persons 9
- The Centers for Disease Control and Prevention advises monitoring for drug interactions with terfenadine, rifampin, astemizole, phenytoin, cyclosporine, warfarin, or oral hypoglycemics 9
- The Centers for Disease Control and Prevention notes that topical therapy is generally free of systemic side effects 9
Critical Pitfalls to Avoid
- The Centers for Disease Control and Prevention recommends against routinely testing for HIV in women with RVVC who lack HIV risk factors 9
Risk Factors for Vulvovaginal Candidiasis and the Non‑Association with Menopause
Established Predisposing Factors
- The CDC guidelines identify diabetes mellitus, pregnancy, and oral‑contraceptive use as well‑established predisposing risk factors for vulvovaginal candidiasis, while menopause is not recognized as a risk factor. 10